QCG
ITOS

Quadrant Capital Group’s iTeos Therapeutics ITOS Stock Holding History

Quadrant Capital Group’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-135
Closed -$1.04K – 2802
2024
Q4 		$1.04K Sell
135
-596
-82% -$5.12K ﹤0.01% 2585
2024
Q3 		$7.46K Hold
731
– – ﹤0.01% 2225
2024
Q2 		$10.8K Sell
731
-90
-11% -$1.29K ﹤0.01% 2093
2024
Q1 		$11.2K Sell
821
-7
-0.8% -$76 ﹤0.01% 2060
2023
Q4 		$9.07K Buy
828
+245
+42% +$2.43K ﹤0.01% 2097
2023
Q3 		$6.38K Sell
583
-1,611
-73% -$20.6K ﹤0.01% 2113
2023
Q2 		$29K Buy
2,194
+2,170
+9,042% +$30.9K ﹤0.01% 1528
2023
Q1 		$327 Sell
24
-383
-94% -$6.86K ﹤0.01% 2642
2022
Q4 		$7.95K Buy
+407
New +$7.95K ﹤0.01% 2060

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Quadrant Capital Group's ITOS Position: Q1 2025 in Review

Quadrant Capital Group sold out of iTeos Therapeutics (ITOS) in Q1 2025, closing a stake of 135 shares — an estimated $1.04K sold.

Quadrant Capital Group first reported a position in ITOS in Q4 2022 and held it in 9 quarters. The position peaked at $29K in Q2 2023. 131 funds tracked by Wall St. Rank hold ITOS as of Q1 2025.

  • Quadrant Capital Group reported no remaining iTeos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 135 iTeos Therapeutics shares in Q1 2025, an estimated $1.04K.
  • Quadrant Capital Group first reported a position in iTeos Therapeutics in Q4 2022 and held it in 9 quarters.
  • Quadrant Capital Group's iTeos Therapeutics position peaked at $29K in Q2 2023.
  • 131 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2025.

Based on Quadrant Capital Group's 13F filing for Q1 2025, filed 13 May 2025.